        |
|
 MultiCell Announces Intellectual Property Portfolio of First-in-Class Technologies Crosses Threshold of 50 Issued or Pending Patents MultiCell Technologies, Inc. (OTCBB: MCET), a biopharmaceutical company developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that its intellectual property portfolio now totals 54 issued or pending patents that cover its novel drug development platform technologies and new drug candidates. The Company is leveraging its breakthrough technology platforms to develop a new generation of therapeutic candidates which stimulate or suppress the immune system to treat such conditions as multiple sclerosis, diabetes and infectious and viral diseases such as HIV. "The aggressive expansion of our patent portfolio is central to both our scientific as well as our growth strategies. Achievement of this latest threshold of 54 issued or pending patents is an indication of our commitment to extend MultiCell's leadership as a developer of the next generation of immune-modulating drug therapies," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "Through our key drug development platforms, MultiCell is taking a leadership role in creating first-in-class immune-modulation drugs to target extensive unmet medical needs." The US Patent and Trademark Office recently published MultiCell's US patent application (US Patent Application 20060193855) for its novel therapeutic immunoglobulin-peptide molecules which target disease-specific T-cells. MultiCell also recently announced it has filed a patent that provides a potential new cancer therapy via a method for treating a range of malignant tumors using the Company's unique technologies to manipulate the immune system. Modulation of the immune system is central to humans' ability to combat disease. MultiCell's therapeutic development strategy targets both the innate and adaptive immune systems via platform technologies known as Toll-like receptors and disease-specific T-cell targeting. MultiCell is leveraging its platform technologies to develop new drug candidates that effectively ward of disease; some by boosting the immune response, such as would be needed in the case of virus infection. Other MultiCell drug candidates are designed to selectively suppress only those immune cells which are the underlying cause of such serious and difficult-to-treat diseases such as multiple sclerosis or type-1 diabetes. "MultiCell is developing technologies and drug candidates that can be described as the fourth generation of immune system therapeutics," Dr. Chang added. "They are continuing in the tradition of the immunological research that saved lives with the first vaccines, then progressed to immune suppression therapy, and more recently to multibillion-dollar markets for targeted immune system-based therapies." MultiCell is currently focused on three disease targets with products already in the clinic: multiple sclerosis (MS), type-1 diabetes, and influenza. The Company's first-in-class therapeutic pipeline includes: -- MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world. -- MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models. -- MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models. -- MCT-465 for the treatment of virus infection. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. About MultiCell Technologies MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications and the production of therapeutic proteins, and is the leading producer of immortalized human hepatocyte cell lines needed by the biotechnology and pharmaceutical industries to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference/html. Forward-Looking Statements Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward-looking statements include statements regarding plans to develop new drug candidates, plans to expand intellectual property holdings, the ability of MultiCell to accelerate any of its therapeutic programs, or the ability of MultiCell to commercialize any drug candidates. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statements include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events. MultiCell Technologies, Inc. |